Navigation Links
Mast Therapeutics Reports Fourth Quarter And Full Year 2012 Financial Results
Date:3/19/2013

oss for the year ended December 31, 2012 was $15.6 million, or $0.33 per share (basic and diluted), compared to a net loss of $13.3 million, or $0.47 per share (basic and diluted), for the same period in 2011.

R&D expenses for the year ended December 31, 2012 were $8.1 million, an increase of $2.3 million, or 41%, compared to $5.8 million for the same period in 2011. The increase was due to a $1.2 million increase in personnel costs, a $0.6 million increase in external clinical study fees and expenses and a $0.5 million increase in external nonclinical study fees. The increase in personnel costs was primarily related to additional clinical and research-related manufacturing staff hired in 2012, including relocation and recruitment costs for our new Chief Medical Officer. The increase in external clinical study fees and expenses was related primarily to a $0.8 million increase in clinical consulting and phase 3 study planning expenses for MST-188, offset by a $0.2 million decrease in clinical consulting expenses for ANX-514 and ExelbineTM.  The increase in external nonclinical study fees and expenses was related primarily to a $2.0 million increase in research-related manufacturing activities and regulatory affairs-related consulting expenses for MST-188 and a $0.7 million increase in research-related manufacturing activities for ANX-514, offset by a $2.2 million decrease in commercial-readiness manufacturing activities for Exelbine.  Due to its focus on MST-188, the Company elected to discontinue independent development of its ANX-514 and Exelbine programs in 2012 and 2011, respectively.

SG&A expenses for the year ended December 31, 2012 were $7.5 million, an increase of $0.3 million, or 5%, compared to $7.2 million for the same period in 2011. The net increase resulted from a $0.7 million increase in personnel costs, mainly due to additional staff hired in 2012, and a $0.5 million increase in share-based compensation expe
'/>"/>

SOURCE Mast Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Echo Therapeutics Achieves ISO 13485 Certification
2. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
3. Echo Therapeutics Appoints Robert Doman to Board of Directors
4. Autoinjectors to 2018 Devices, Therapeutics, Markets, Strategies and Prospect
5. ADVENTRX Completes Name Change To "Mast Therapeutics, Inc."; New Ticker Symbol: "MSTX"
6. Cell Therapeutics to Present at the ROTH Capital Partners 25th Annual Growth Stock Conference
7. PTC Therapeutics Closes $60 Million Private Financing
8. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
9. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
10. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
11. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Research and ... addition of the "Global Gynecological Devices ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... into wide categories based on their operations. ... of different gynecological conditions that affect the ...
(Date:9/19/2014)... , Sept. 19, 2014  The board of ... declared a quarterly cash dividend of $0.42 per share.  ... 17, 2014 to stockholders of record at the close ... AbbVie AbbVie is a global, research-based biopharmaceutical company formed ... is to use its expertise, dedicated people and unique ...
(Date:9/19/2014)... , Sept. 19, 2014  For Cloud Pharmaceuticals, ... design and development, partnering is an integral part ... to design new drugs and identify early stage, ... to further their development. The company also partners ... support this business model, Cloud Pharmaceuticals will be ...
Breaking Medicine Technology:Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2
... Mass. and SYDNEY, Dec. 2, 2010 HeartWare International, ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that CEO Doug Godshall is scheduled to ... & Obesity Conference on Tuesday, December 7, 2010 at ...
... Dec. 2, 2010 Sagent Pharmaceuticals, Inc., a ... approval and launch of its topotecan hydrochloride for ... innovator,s patent expiry.  Sagent,s topotecan is available in ... latest product to feature Sagent,s proprietary PreventIV Measures™ ...
Cached Medicine Technology:HeartWare to Present at the Canaccord Genuity Cardio/Diabetes & Obesity Conference 2Sagent Pharmaceuticals Adds to Its Oncology Portfolio With Launch of Topotecan Hydrochloride for Injection 2
(Date:9/21/2014)... OH (PRWEB) September 21, 2014 C8 ... District of Ohio as the list of 20 possible ... been narrowed down to six, reports Wright & Schulte ... chosen from the almost 2500 C8 lawsuits filed that ... or testicular cancer as a result of being exposed ...
(Date:9/20/2014)... September 21, 2014 Recently, iFitDress.com, a well-known ... of beautiful party dresses . In addition, the company ... main aim of the promotion is to benefit all of ... in its online store now. , Along with beautiful ... graceful items. It has recently released its new sexy short ...
(Date:9/20/2014)... September 21, 2014 Weight Destroyer ... by fitness expert Michael Wren that has already helped ... and reverse health conditions like high blood pressure, high ... Shane Michaels, prompting an investigative review. , “Weight ... tips upside down by showing people what is truly ...
(Date:9/20/2014)... Mexico (PRWEB) September 20, 2014 The ... including Villa del Palmar Cabo San Lucas, Villa La ... relation to Hurricane Odile, with plans to welcome guests ... , As of Sept. 19, all members and guests ... home, thanks to a coordinated effort with government authorities. ...
(Date:9/20/2014)... Ticket Down is a dependable source ... popular ticket exchange is offering their customer appreciation promo code ... of tours is beginning to fill up. Many of the ... hit the road, including 21-year-old pop superstar, Ariana Grande. Grande, ... which will take her to 25 cities across the United ...
Breaking Medicine News(10 mins):Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 2Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 3Health News:C8 Lawsuit Claims Move Forward as Six Possible Cases for Bellwether Trials Selected in DuPont Water Contamination Lawsuits, Reports Wright & Schulte LLC 4Health News:Beautiful Party Dresses For Autumn Unveiled By iFitDress.com 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 2Health News:Weight Destroyer: Review Exposes Michael Wren’s Guide to Effective Weight Loss and Improved Health 3Health News:Villa Group Resorts in Cabo Largely Unharmed, Plan to Re-open Early October 2Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 2Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 3
... Plavix trial shows double dosage best for angioplasty ... they digest the latest news on what dose of ... are looking at the next generation of clot-busters that ... buzz among cardiologists at last week,s Transcatheter Cardiovascular Therapeutics ...
... Communication woes still plague medical system, researchers find ... an advanced, computerized medical-record system with alerts cannot ... when imaging tests turn up signs of trouble, ... that an electronic medical record that facilitates transmission ...
... but any amount helps, experts say , MONDAY, Sept. 28 ... obese may triple the chances of eliminating their sleep problems ... 10 percent of their body weight was enough to bring ... the Center for Obesity Research and Education at Temple University ...
... Neurology suggests that impaired kidney function is a ... The study, conducted by researchers at Rush University Medical ... cognition related to memory functions. Damage to one of ... associated emotions and other contextual knowledge, is often the earliest ...
... ANN ARBOR, Mich.---The Great Depression had a silver lining: During ... years, according to a University of Michigan study published in ... Academy of Sciences . Life expectancy rose from 57.1 ... analysis by ,U-M researchers Jos A. Tapia Granados and Ana ...
... Mich. (Sept. 28, 2009) Van Andel Research ... ways to treat Myelodysplastic Syndrome (MDS), a bone marrow disease ... United States, and that sometimes results in acute myeloid leukemia. ... the disease,s progression and could prove to be a therapeutic ...
Cached Medicine News:Health News:Clot-Busting Therapy Under Review 2Health News:Clot-Busting Therapy Under Review 3Health News:Docs Miss Test Results -- Even With Alerts 2Health News:When Pounds Go, Sleep Apnea May Improve 2Health News:When Pounds Go, Sleep Apnea May Improve 3Health News:Impaired kidney function linked to cognitive decline in elderly 2Health News:U-M study: Life and death during the Great Depression 2Health News:U-M study: Life and death during the Great Depression 3Health News:Van Andel Institute researchers find gene that could lead to new therapies for bone marrow disease 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: